Clinical trials bureaucracy: unintended consequences of well-intentioned policy
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BackgroundAs randomized controlled trials have become the ‘gold standard’ for medical research, a complex regulatory structure for the conduct of clinical trials has emerged. However, this structure has not been adequately assessed to ensure that regulations governing human subjects research actually produce the desired effects. PurposeOur purpose is to identify some of the major shortcomings in the current regulatory system of human clinical trials oversight, and to propose some potential solutions to these problems. MethodsWe discuss the evolution of the current US regulatory environment and its application in the context of several widely-used drug therapies. ResultsDespite numerous randomized controlled trials, performed within a structure of extensive documentation and data collection, serious shortcomings in a number of pharmaceutical therapies were not detected until after the drugs were approved and widely adopted by clinicians. ConclusionThe current system of regulatory bureaucracy in clinical trials has led to an extremely expensive research paradigm that, in spite of complex systems of oversight and exhaustive data collection, cannot be shown to adequately ensure the integrity of the research process and the protection of human research subjects. Some parts of the system, including Research Ethics Review Boards, may not be well-suited to carrying out their core mission of overseeing research conduct, and other aspects of clinical trials regulatory structure, such as monitoring/auditing review and adverse event reporting, may constitute a waste of money and resources. Misdirected data collection and adverse events reporting divert valuable resources and hamper development of large, simple clinical trials powered to definitively answer important research questions. Careful scrutiny of the utility of current or proposed regulatory schemes is required to ensure the integrity of human subjects research and to enhance the effectiveness of research dollars.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331 · cited 1×
“Selective serotonin reuptake inhibitor (SSRI) antidepressants seem to cause an increase in suicidal ideation [22], and 10% of American boys are said to be taking drugs to treat attention deficit disorder that are known to raise heart rate and blood pressure, and for which anecdotal cases of sudden death have been repo…”
Background
Cited by
Increasing value and reducing waste in biomedical research regulation and management
Salman, R. A.-S., Beller, E., Kagan, J., Hemminki, E., Phillips, R. S., Savulescu, J., Macleod, M., Wisely, J., & Chalmers, I. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62297-7 · Cited by 534
De testimonio: on the evidence for decisions about the use of therapeutic interventions
Rawlins, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61930-3 · Cited by 362
The unintended consequences of clinical trials regulations
McMahon, A. D., Conway, D. I., MacDonald, T. M., & McInnes, G. T. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000131 · Cited by 73
“Robert Califf notes that this is a ‘‘colossal waste of money,’’ and that a more effective and scientific method would be to use sampling and the statistical process control techniques that are found in other industries (such as engineering and manufacturing) [41].”
BackgroundManagement of endometriosis: Toward value-based, cost-effective, affordable care
Vercellini, P., Facchin, F., Buggio, L., Barbara, G., Berlanda, N., Frattaruolo, M. P., & Somigliana, E. (2018) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.07.011 · Cited by 36
Regulatory Frameworks for Clinical Trial Data Sharing: Scoping Review
Gudi, N., Kamath, P., Chakraborty, T., Jacob, A. G., Parsekar, S. S., Sarbadhikari, S. N., & John, O. (2022) · Journal of Medical Internet Research · doi:10.2196/33591 · Cited by 31
“There are ethical complexities as well: large sample sizes are often possible only by recruiting participants from low-income countries owing to their larger populations and (often) poor clinical trial oversight and regulatory mechanisms [19,31].”
Background
Metadata
- Authors
- Califf, R. M.
- Venue
- Clinical Trials
- Publisher
- SAGE Publications
- Published
- 2006-12
- Volume
- 3
- Issue
- 6
- Pages
- 496-502
- ISSN
- 1740-7745 (ISSN-L)
- 1740-7753
- OpenAlex
- W1978821900
- Cited by
- 91
- References
- 3
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trials bureaucracy: unintended consequences of well-intentioned policy. https://app.cochat.ai/papers/10.1177/1740774506073173
- The paper
- Califf, R. M. (2006). Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clinical Trials. https://doi.org/10.1177/1740774506073173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.